HBsAg Testing in the Push Toward Hepatitis B Elimination: Screening, Diagnostics, and Global Targets

The WHO 2030 Elimination Framework and the Centrality of HBsAg

In 2016 the World Health Assembly endorsed a global health sector strategy that set, for the first time, quantitative elimination targets: a 90% reduction in new chronic hepatitis B infections and a 65% reduction in hepatitis B-related deaths by 2030, measured against a 2015 baseline. The cascade of care that delivers these goals begins with a deceptively simple step — knowing who is infected. Because the large majority of people living with chronic HBV are asymptomatic for years or decades, "hepatitis B symptoms" such as fatigue, jaundice, or abdominal discomfort appear only after substantial liver injury has occurred. By then, opportunities for prevention and treatment have narrowed. HBsAg testing is therefore the gateway intervention: it converts an invisible epidemic into a countable, treatable, and preventable population.

The scale of the gap is sobering: global surveys suggest that only about one in ten people with chronic HBV knew they were infected in recent years, with treatment coverage lagging further behind. Reaching the 2030 diagnostic target of 90% identified therefore requires moving decisively beyond passive, hospital-based testing toward community, antenatal, and risk-based screening built around the HBsAg test.

Figure 1. Prevalence of hepatitis B surface antigen positivity by country of birth. (Source: Zhou K, et al. 2024)

Mother-to-Child Transmission and the Birth-Dose Vaccine

No intervention illustrates the power of HBsAg screening better than the prevention of mother-to-child transmission. Infants infected perinatally have a roughly 90% chance of developing chronic infection, and chronic infection acquired at birth carries a 15–25% lifetime risk of cirrhosis or liver cancer. The "hepatitis B vaccine" given as a birth dose within 24 hours, combined with hepatitis B immune globulin where available, reduces that risk dramatically. Yet the birth dose remains poorly delivered: in parts of sub-Saharan Africa, timely coverage has lingered in the single digits.

Antenatal HBsAg screening is the necessary precondition. Recent prospective work in Cameroon showed that even with a correctly timed birth dose, a measurable residual risk of transmission persists — concentrated in mothers who were HBeAg-positive or had high HBV DNA. This reframed the conversation toward "screen-and-treat": identifying HBsAg-positive pregnant women and, where viremia is high, offering peripartum antiviral prophylaxis. Feasibility studies in the Democratic Republic of the Congo demonstrated that layering HBV testing and maternal treatment onto existing HIV prevention-of-mother-to-child-transmission programs is acceptable and workable, pointing to a scalable blueprint for high-burden settings.

Occult HBV Infection: When the Surface Antigen Disappears

One of the more counterintuitive challenges in hepatitis B diagnostics is occult HBV infection. By definition, occult infection is the presence of replication-competent HBV — typically demonstrable in liver tissue and often in blood by nucleic-acid testing — in a person whose standard HBsAg test is negative. It can follow spontaneous or treatment-associated HBsAg loss, arise from surface-gene escape mutants that evade detection, or occur in people whose only serological footprint is an isolated anti-HBc result.

Why does it matter for elimination? First, occult HBV can reactivate under immunosuppression, sometimes causing severe hepatitis. Second, it is a recognized co-factor in hepatocellular carcinoma, particularly where HCV or cryptogenic liver disease is present. Third, it complicates blood and organ safety. For researchers, occult infection is a reminder that sensitive antigen and antibody reagents, plus nucleic-acid methods, must be interpreted together rather than in isolation.

Research and Surveillance Utility of HBsAg Antigen and Antibody Reagents

Beyond the clinic, HBsAg and its corresponding antibodies are foundational research tools. Recombinant HBsAg preparations let investigators study virus-like particle assembly, immune escape, and vaccine immunogenicity without handling infectious material. Research-grade anti-HBs antibodies are used to capture and quantify surface antigen in quantitative immunoassays, to map epitopes within the "a" determinant, and to develop the next generation of more sensitive, lower-detection-limit assays that may one day resolve the grey zone between occult infection and true clearance.

Standardized reagents also make trend data comparable across time and geography. National hepatitis programs, blood services, and academic groups all rely on shared reference materials to report HBsAg prevalence consistently — the very denominator that the 2030 elimination math depends upon. The surface antigen and the reagents built around it quietly underpin the global accounting of progress.